Actelion Pharmaceuticals US, Inc.
Profile
Actelion, a leader in Pulmonary Arterial Hypertension, became a part of the Janssen Pharmaceutical Companies of Johnson & Johnson following its acquisition in June 2017. Actelion’s medicines have helped to expand and strengthen Janssen’s portfolio. Janssen has added Pulmonary Hypertension as a therapeutic area of focus to maintain the leadership position Actelion has built in this rare disease area.